Peyronie’s disease is sometimes called “curved privates disease” or simply “curvature” because the scar tissue (or plaque) causes the privates to bend when aroused. However, many curved privates are ...

WHAT IS PEYRONIE’S DISEASE? CAUSES, EFFECTS, AND TREATMENT OPTIONS Peyronie’s Disease is a condition where the penis bends or curves abnormally during an erection, often accompanied by pain. While ...

It’s important to see your doctor or find a specialist when you first notice signs of Peyronie’s disease, a condition where scar tissue develops on the penis, causing curved and sometimes painful ...

DEAR READER: Peyronie’s disease is, fortunately, relatively uncommon. About 5 percent of men in the United States may have it. The condition affects the penis. It causes inflammation and then scar ...

Analysis of men seen at a specialist clinic provides new insights into the classification of Peyronie's disease (PD) subtypes, according to a report in the September issue of The Journal of Urology®, ...

Peyronie's disease (PD) is an acquired inelastic scar of the tunica albuginea of the penis, resulting in penile pain, curvature and other deformities, and sexual dysfunction, as well as significant ...

With a condition like Peyronie’s disease, you’ll want to find a doctor who focuses on your specific needs. A specialist can help. Peyronie’s specialists are doctors who work carefully with the ...

MALVERN, Pa., Oct. 15, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today that a presentation related to Peyronie's disease, or PD, and XIAFLEX ® (collagenase ...

Peyronie’s Disease Treatment Market Market has potentials to grow as the most influential market worldwide as it has been playing a noteworthy role in imprinting positive impacts on the international ...

The 90-second commercial builds on the "Bent Carrot" campaign, launched in 2021, with creative that highlights a couple's journey from diagnosis to treatment. It spotlights the copay program designed ...

MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...